The global cancer diagnostics market size was valued at USD 160.5 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.89% from 2022 to 2030. Increasing number of cancer cases globally is one of the major factors contributing to industry growth during the forecast period. Technological advancements in diagnostic tests are further expected to fuel industry growth. Moreover, supportive government initiatives and rising awareness are some additional factors anticipated to boost the growth during the forecast period. For instance, the Biden-Harris administration has set a goal of decreasing the cancer mortality rate by 50% over the following 25 years and enhancing the knowledge of people living with and surviving tumors.
COVID-19 has placed an unprecedented strain on healthcare systems globally. It has led to challenges in offering care while minimalizing the spread of the virus and created a great demand for hospital resources. Healthcare systems across the world have struggled to adjust to the challenges posed by the COVID-19 pandemic. Subsequently, surgeons have seen a lessening number of elective procedures executed since the pandemic began. Planned oncology surgeries have been affected by this rescheduling of non-urgent elective operations. Patients with tumors are at a high risk of infection. Furthermore, morbidity and mortality from COVID-19 are increased in patients with cancer. As per the report by the American Society of Clinical Oncology in March-July 2020 in comparison with 2019, there was a considerable decrease in biopsies, tumor screenings, office visits, therapy, and surgeries. In April 2020, at the peak of the pandemic, screenings for colon, breast, lung, and prostate cancers were lower by 75%, 85%, 56%, and 74%, respectively. Additionally, in March 2020 alone, the COVID-19 pandemic forced the delay of more than 800 appointments for the screening of lung cancer. Even after the screening resumed to a normal schedule, the percentage of new patients screening remained low.
Cancer is one of the leading causes of death across the world and the prevalence of the disease has been escalating at an alarming rate. Therefore, healthcare professionals are focusing on the development of effective screening and treatment solutions to check prevalence levels. Early screening increases the success rate of treatment regimens. As a result, healthcare agencies and market players, through various awareness programs, are promoting routine check-ups and screenings. For instance, in March 2022, HHS announced funding of USD 5 million to improve equity in the screening of cancer at health centers.
The global oncology burden is projected to reach 28.4 million cases in 2040, a 47% upsurge from 2020. Thus, rise in the incidence is anticipated to boost the adoption of cancer diagnostic products. In April 2022, the Precision Cancer Consortium (PCC) collaborated with pharmaceutical companies by permitting access to comprehensive testing for all cancer patients globally. The PCC drives diversity of initiatives aimed at growing patient access to precision diagnostics using wide-ranging genomic testing including NGS. The founding members of PCC include Novartis, Bayer, Roche, and GlaxoSmithKline.
Technological advancements in diagnostic testing are further expected to fuel market growth during the forecast period. For instance, in November 2021, Hologic, Inc. announced the commercial accessibility of the Genius Digital Diagnostics System in Europe. The system is the next-generation cervical cancer screening, which combines the deep learning-based AI with innovative volumetric imaging technology to help identify the cervical cancer cells and pre-cancerous lesions in women. In addition, in March 2022, Hartford HealthCare and Ibex Medical Analytics announced a research initiative involving Ibex's ‘Galen Breast’, an Artificial Intelligence solution helping doctors deliver high-quality enhanced care and screening for breast cancer patients. Thus, such growing initiatives by the key players are expected to boost the industry growth in the near future.
Rising number of programs to raise awareness about malignant tumor screening by various organizations is a key factor responsible for the increased demand for diagnostic products worldwide. Collaborations and partnerships undertaken by the National Cervical Cancer Coalition, the WHO, the CDC, and the U.S. Preventive Services Task Force for increasing cervical cancer screening are expected to boost industry growth during the study period. Moreover, several countries have undertaken measures to increase screening for early screening and help the existing patients. For instance, the Indian government has initiated the Ayushman Bharat and the Prime Minister’s National Relief Fund for patients who require assistance during the treatment.
The consumables segment held the largest share of over 60.0% in 2021 and is anticipated to maintain this position throughout the forecast period. Increasing usage of consumables, increased R&D expenditure, an increase in the geriatric population, and the launch of technologically advanced diagnostic kits and reagents are fueling the growth of the segment.
In January 2020, Sysmex Corporation launched ipsogen JAK2 DX reagent. It is a gene testing kit, which measures the JAK2V617F mutation quantitatively, which is used for the screening of blood cancers. In addition, in January 2020, the product gained health insurance coverage, becoming Japan’s first diagnostic product to be covered. Moreover, the tests using this reagent will be covered under the health insurance. This is anticipated to boost the opportunities for more patients to receive testing.
In September 2022, Precipio, Inc. has signed a distribution agreement for HemeScreen with a major distribution partner in the U.S. The company continues to carry out its HemeScreen distribution expansion strategy of a multi-pronged method by targeting the national and regional hospital networks, physician-owned laboratories, and reference labs. The diversity of channel partners and distributors engaging with Precipio augments its market potential.
The IVD testing held the largest share of over 60.0% in 2021 owing to factors such as increasing adoption of in-vitro diagnostics. Increasing number of in vitro diagnostics products being launched by the major market players is also fueling the growth of the market. For instance, in Feb 2022, Invitae launched LiquidPlex Dx and FusionPlex Dx in Europe. The product launch will increase patients’ access to cancer diagnostics in Europe. Moreover, in June 2022, Biocartis Group NV launched its fully automated Idylla GeneFusion Panel for non-small cell lung cancer. The panel is designed for use in clinical laboratories and provides complete testing results within 180 minutes, considerably faster than recently available testing methods, which frequently take days or even weeks for the results.
The IVD testing segment is further sub-segmented into polymerase chain reaction, in situ hybridization, immunohistochemistry, next-generation sequencing, microarrays, flow cytometry, immunoassays, and other IVD testing technologies. PCR held the largest market share in 2021 as PCR-based techniques need comparatively simple infrastructure and instrumentation, utilize only small amounts of biological material, and are extremely compatible with the clinical routine. NGS is expected to grow at the fastest rate during the review period.
Biopsy technique is expected to be the fastest-growing segment during the forecast period. Biopsy is one of the most significant screening techniques for cancer detection. This screening technique has revolutionized breast, prostate, and skin cancer diagnoses to a great extent. An increase in the global number of cancer cases has spurred the demand as well as supply of biopsy devices.
Furthermore, a global shift in consumer preference toward minimally invasive surgical procedures owing to growing awareness about associated benefits such as faster recovery times, smaller incisions, and reduced pain and scarring further propel investment in the space.
The laboratory tests segment held the largest share of over 25.0% in 2021 owing to rise in the prevalence of cancer. While conducting laboratory tests for cancer, samples of urine, blood, or other body fluids or tissues are examined for tumor markers or abnormal cells that help determine if an individual has a precancerous condition or cancer. Laboratory tests are also used to screen high-risk patients, identify various treatment options, pinpoint disease stage, and evaluate if the disease is responding to treatment. These tests help determine if a patient has cancer recurrence, or a new tumor has developed.
Rising number of research activities undertaken by various academic and research organizations is also expected to fuel the market growth during the forecast period. For instance, in August 2021, The Cancer Prevention and Research Institute of Texas (CPRIT) announced new 74 cancer research and grants on prevention for over USD 112 million. The projects approved include 7 prevention awards, 65 academic research grant awards, and research for the development of 2 product awards, which is granted to 16 companies and institutions across the state. These awards will increase clinical trial access, support groundbreaking research, and deliver much needed cancer screening.
The biopsy segment is expected to grow at the fastest rate during the forecast period due to various benefits associated with the test, including early detection of cancer. In addition, biopsy helps determine how aggressive the disease is and how likely it is to spread to other organs. A biopsy helps in the selection of a specific treatment plan, depending on the spread of tumor. Furthermore, key operating players have introduced innovative products for market expansion, thus driving the market. For instance, in February 2021, Twist Bioscience Corporation launched Twist NGS Methylation Detection System for liquid biopsy cancer analysis and epigenetic studies.
The hospitals and clinics segment led the global market in 2021 and accounted for a revenue share of more than 50.0%. Factors such as increasing awareness regarding personalized medicine, upsurge in affordable healthcare services, and strategic activities are fueling the segment growth. For instance, in December 2021, City of Hope acquired Cancer Treatment Centers of America for USD 390 million to build a national, integrated research and treatment system for cancer. The joint entity will be one of the major cancer treatment and research organizations in the U.S. with one of the leading geographic footprints, serving nearly 115,000 patients every year.
The diagnostic laboratories segment is expected to expand at the fastest CAGR over the forecast period owing to the large volume of testing performed in the laboratories, coupled with favorable reimbursement policies. For instance, in 2018, CMS finalized a National Coverage Determination, which covers diagnostic laboratory tests using NGS for patients with advanced cancer, thereby increasing access and expanding coverage to patients.
The others segment dominated the market and held a share of over 20.0% in 2021. The breast cancer segment held the second-largest share in 2021. Growth of R&D in advanced screening tools for breast cancer is anticipated to boost the segment growth significantly. In March 2022, Paige launched Paige Breast Lymph Node, an Artificial Intelligence medical device software, which helps pathologists identify if breast cancer has grown to lymph nodes.
Moreover, in September 2022, Optellum raised USD 14 million in a Series A funding round. The investment will enable the company to scale its operations, base, and commercial launches in the U.S. and the U.K.; fast-track the R&D; and expand its platform for personalized therapy evaluations. Additionally, growth in initiatives to spread awareness among individuals is expected to boost the market growth. In April 2022, the Department of Health & Family Welfare, Roche Pharma India, Niramai Health Analytix, and the Government of Punjab have signed a partnership to fast-track Breast cancer treatment and screening in the state of Punjab.
North America held the largest share of over 40.0% in 2021. Increasing strategic activities by key players are driving the market in this region. For instance, in March 2021, Agilent acquired Resolution Bioscience Inc. The acquisition expands and complements the company’s competencies in NGS-based cancer diagnostics and provides the company with advanced technology to serve the needs of the increasing precision medicine market.
Asia Pacific is estimated to be the fastest-growing region over the forecast period due to strategic initiatives undertaken by major players, a considerable rise in cervical screening programs conducted to increase awareness and screening, a rise in R&D, and technological advancements. For instance, in November 2019, the Australian Cervical Cancer Foundation (ACCF) launched National Cervical Cancer Awareness Week 2019. The ACCF aims at eliminating cervical cancer by 2035 by increasing awareness among women across Australia. Hologic Inc. is one of the sponsors of ACCF screening programs.
Key players in this market are implementing various strategies including partnerships, mergers and acquisitions, geographical expansion, and strategic collaborations to expand their market presence. For instance, in November 2021, GE Healthcare collaborated with SOPHiA GENETICS, Optellum, and The University of Cambridge to make precision health more accessible and advance outcomes for patients. Some prominent players in the global cancer diagnostics market include:
F. Hoffmann-La Roche Ltd.
Siemens Healthcare GmbH
Thermo Fisher Scientific, Inc.
Koninklijke Philips N.V. (Philips)
Market size value in 2022
USD 172.3 billion
Revenue forecast in 2030
USD 293.5 billion
CAGR of 6.89% from 2022 to 2030
Base year for estimation
2018 - 2020
2022 - 2030
Revenue in USD million/billion and CAGR from 2022 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, technology, screening type, application, end-user, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; U.K.; France; Italy; Spain; China; Japan; India; Thailand; South Korea; Brazil; Mexico; Argentina; Columbia; South Africa; Saudi Arabia; UAE
Key companies profiled
GE Healthcare; Abbott; F. Hoffmann-La Roche Ltd; Qiagen N.V.; Becton Dickinson & Company; Siemens Healthcare GmbH; Thermo Fisher Scientific, Inc.; Hologic, Inc.; Koninklijke Philips N.V. (Philips); Illumina, Inc.
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global cancer diagnostics market report on the basis of product, technology, screening type, application, end-user, and region:
Product Outlook (Revenue, USD Billion, 2018 - 2030)
Kits & Reagents
Technology Outlook (Revenue, USD Billion, 2018 - 2030)
Polymerase Chain Reaction (PCR)
In Situ Hybridization (ISH)
Next-generation Sequencing (NGS)
Other IVD Testing Technologies
Magnetic Resonance Imaging (MRI)
Computed Tomography (CT)
Positron Emission Tomography (PET)
Screening Type Outlook (Revenue, USD Billion, 2018 - 2030)
Others (Barium Enema)
Application Outlook (Revenue, USD Billion, 2018 - 2030)
End-user Outlook (Revenue, USD Billion, 2018 - 2030)
Hospitals and Clinics
Regional Outlook (Revenue, USD Billion, 2018 - 2030)
Middle East and Africa (MEA)
b. The global cancer diagnostics market size was estimated at USD 160.5 billion in 2021 and is expected to reach USD 172.3 billion in 2022.
b. The global cancer diagnostics market is expected to grow at a compound annual growth rate of 6.89% from 2022 to 2030 to reach USD 293.5 billion by 2030.
b. The breast cancer segment held the largest share of 14.5% in the overall market in 2021. The growth of R&D in advanced screening tools for breast cancer is anticipated to boost the segment significantly.
b. Major players competing in the cancer diagnostics market include GE Healthcare; Abbott; F. Hoffmann-La Roche Ltd; Qiagen N.V.; Becton Dickinson & Company; and Siemens Healthcare GmbH.
b. The rising prevalence of cancer cases, constant technological advancements in diagnostics, and increasing demand for effective screening tests are some of the prime factors spurring demand for cancer screening tools and techniques across the world.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.